# Kardigan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kardigan

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.kardigan.bio
- Total disclosed funding: $303M
- Latest round: Series B (Oct 14, 2025)
- Investors on record: 6

## About

Established in 2023, and based in California, US, Kardigan, Inc. engages in providing cardiovascular treatments. Kardigan is developing a portfolio of advanced cardiovascular therapeutics to modify the underlying causes of cardiovascular diseases. The offerings consist of late-stage clinical candidates that target critical disease drivers, facilitating effective patient segmentation and streamlined clinical trials. By utilising a proprietary set of cardiac-specific tools, Kardigan validates markers for safety, efficacy, and patient selection in human studies. The company leverages real-world clinical data to enhance its understanding of cardiovascular diseases and the potential impact of its therapies. The products cater to healthcare providers, including hospitals and specialty clinics.

## Funding rounds

- Series B, Oct 14, 2025, $254M — ARCH Venture Partners, T Rowe Price, Fidelity Investments, Sequoia Heritage
- Series A, Jun 24, 2024, $49M — ARCH Venture Partners, Hong Shan, Perceptive Advisors

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Hong Shan — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Sequoia Heritage (https://capitalatlas.ai/funds/sequoia-heritage) — Series B